Recce Pharmaceuticals Ltd (ASX:RCE)

Market Cap	108.44M
Revenue (ttm)	9.59M
Net Income (ttm)	-17.94M
Shares Out	289.18M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,293
Average Volume	117,261
Open	0.3900
Previous Close	0.3870
Day's Range	0.3750 - 0.3900
52-Week Range	0.2750 - 0.5700
Beta	0.54
RSI	55.94
Earnings Date	Aug 29, 2025

About Accolade

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. Its lead candidate is RECCE 327 (R327) for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The company also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, its product pipeline comprises R327 Intravenous, which is in Phas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RCE

Financial Performance

In 2024, Recce Pharmaceuticals's revenue was 5.03 million, an increase of 15.19% compared to the previous year's 4.37 million. Losses were -17.66 million, 35.1% more than in 2023.